SuperworthREGENXBIO PE ratio RGNX
Share price divided by earnings per share over the last twelve months, since 2018.
- Today, Oct 23, 2026
- n/m
- losses over the last year
- Last meaningful
- 14.0×
- Feb 2023
- 8-year median
- 17.7×
- 8-year range
- 9.5× to 57.1×
- Peer median
- 14.1×
REGENXBIO has no meaningful PE ratio today: it lost $3.79 a share over the last twelve months, and a PE needs earnings.
It was last meaningful in Feb 2023, at 14.0×.
On the days it had one over the last 8 years, its median was 17.7×, from 9.5× in May 2022 to 57.1× in Jul 2018.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2023 | 14.0× | 14.0× | 16.2× |
| 2022 | 14.9× | 9.5× | 18.4× |
| 2021 | n/m a value too high to mean anything | ||
| 2020 | n/m a value too high to mean anything | ||
| 2019 | 17.8× | 17.8× | 21.2× |
| 2018 | 18.3× | 17.3× | 57.1× |
Against its peers
Companies in Biotechnology nearest REGENXBIO's size, closest first, today.
| Company | PE ratio |
|---|---|
| RGNXREGENXBIO | n/m |
| MGTXMeiraGTx | 13.0× |
| PLXProtalix BioTherapeutics | 11.1× |
| VCELVericel | 92.5× |
| ADMAAdma Biologics | 15.3× |
| Peer median | 14.1× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on REGENXBIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.